Video visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More
Leonid S. Metelitsa, MD, PhD
Our research is focused on the immunobiology and therapeutic applications of Vα24-Jα18-invariant natural killer T cells (NKTs). NKTs are an evolutionarily conserved subset of innate lymphocytes that are characterized by expression of an invariant T cell receptor α-chain, Vα24-Jα18, and by reactivity to self- and microbial-derived glycolipids presented by monomorphic HLA class-I-like molecule CD1d. NKTs play a critical role in host defense by bridging innate and adaptive immunity, and they are highly conserved between mice and humans. Mounting evidence from both murine models and human studies indicates that NKTs have potent anti-tumor properties. Through exploring the mechanisms of NKT cell anti-tumor activity, we are developing and testing novel immunotherapeutic strategies against multiple types of cancer.
Our group was the first to observe that infiltration of NKTs into primary neuroblastoma tumors was associated with favorable clinical outcomes (Metelitsa et al., J Exp Med, 2004, Song et al., J. Clin Invest, 2007), a finding that has since been extended to other malignancies. Interestingly, most solid tumors do not express CD1d and we found that NKTs indirectly affect tumor growth by recognizing and eliminating tumor-associated macrophages (TAMs), which provide critical stromal support for neuroblastoma cells (Song et al., J Clin Invest, 2009 and Liu et al., J Clin Invest, 2012).
Capitalizing on the unique properties of NKTs to localize to the tumor site and target TAMs, we sought to develop an NKT-cell based platform for cancer immunotherapy. To that end, we engineered NKTs to express chimeric antigen receptors (CARs) specific for tumor-associated antigens, such as GD2 in neuroblastoma or CD19 in lymphoma. We demonstrated that, unlike CAR T cells, CAR NKT cells effectively localized to the tumor site and showed dual anti-tumor activity against GD2-positive tumor cells and CD1d-positive TAMs (Heczey et al, Blood, 2014). To enhance the therapeutic potential of NKTs and CAR NKTs, we developed an ex vivo expansion method for these cells that preserves the critical CD62L+ subset, which we have found to be required for NKT in vivo persistence and long-term tumor control (Tian et al., J Clin Invest, 2016).
Within the last several years, we have developed cGMP protocols for clinical scale manufacturing of CAR NKT cells. Our optimized second-generation GD2-specific CAR construct that co-expresses cytokine IL-15 has been found to promote NKT cell survival and function within tumor tissues in pre-clinical models (Clin Canc Res, 2019). These efforts have resulted in initiation of the first clinical trial to test CAR NKT cells in humans (NCT03294954). The goal of this phase 1 trial is to evaluate the safety and therapeutic activity of NKT cells expressing a GD2-specific construct in children with neuroblastoma. Preliminary results demonstrate that the therapy is well tolerated and produces anti-tumor activity in neuroblastoma patients (Heczey et al., Nat Med, 2020).
In parallel, we have initiated a first-in-human clinical trial evaluating allogeneic NKT cells (NCT03774654). Unlike T cells, NKTs are not allo-reactive and therefore CAR NKTs prepared from healthy donors can be used on-demand in cancer patients without costly and time-consuming patient-specific cell manufacturing. In this trial, NKTs expressing a novel CD19-specific CAR are being tested in patients with B cell malignancies.
Our research is supported by grants from NIH/NCI, DoD, CPRIT, the Leukemia & Lymphoma Society, Alex’s Lemonade Stand Foundation, and industrial sponsors.